Wikidata

(Q63572414)

English

Study of Sustained Benefit of Erenumab in Adult Episodic Migraine Patients

clinical trial

In more languages
default for all languages
No label defined

No description defined

Statements

title
A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Activecontrolled Study Comparing Sustained Benefit of Two Treatment Paradigms (Erenumab qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients (English)
0 references
sponsor
Amgen
0 references
country
Austria
0 references
Belgium
0 references
Finland
0 references
France
0 references
Germany
0 references
Greece
0 references
Ireland
0 references
Israel
0 references
Italy
0 references
Netherlands
0 references
Poland
0 references
Portugal
0 references
Slovakia
0 references
Spain
0 references
United Kingdom
0 references
start time
20 May 2019
0 references
end time
4 December 2020
0 references
number of participants
600
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63572414&oldid=2234838088"